- Email: [email protected]
Bisoprolol
Bisoprolol See also Beta-adrenoceptor antagonists
GENERAL INFORMATION Bisoprolol is a highly selective b1-adrenoceptor antagonist. Its adverse effects profile is similar to that of atenolol [1], and despite theoretical benefits there is no convincing clinical evidence that bisoprolol has an advantage [2].
ORGANS AND SYSTEMS Metabolism Bisoprolol can increase serum triglycerides and reduce HDL cholesterol [3].
Urinary tract The lower urinary tract symptoms of benign prostatic hyperplasia in a 60-year-old man worsened antihypertensive treatmentwithbisoprolol[4].Withdrawalresultedinrelief,whereas rechallengecausedrepeateddeterioration.
ã 2016 Elsevier B.V. All rights reserved.
DRUG-DRUG INTERACTIONS See Rifamycins
REFERENCES [1] Neutel JM, Smith DH, Ram CV, Kaplan NM, Papademetriou V, Fagan TC, Lefkowitz MP, Kazempour MK, Weber MA. Application of ambulatory blood pressure monitoring in differentiating between antihypertensive agents. Am J Med 1993; 94(2): 181–7. [2] Wheeldon NM, MacDonald TM, Prasad N, Maclean D, Peebles L, McDevitt DG. A double-blind comparison of bisoprolol and atenolol in patients with essential hypertension. Q J Med 1995; 88(8): 565–70. [3] Lancaster SG, Sorkin EM. Bisoprolol. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in hypertension and angina pectoris. Drugs 1988; 36(3): 256–85. [4] Sein Anand J, Chodorowski Z, Hajduk A. Repeated intensification of lower urinary tract symptoms in the patient with benign prostatic hyperplasia during bisoprolol treatment. Przegl Lek 2005; 62(6): 522–3.
GENERAL INFORMATION Bisoprolol is a highly selective b1-adrenoceptor antagonist. Its adverse effects profile is similar to that of atenolol [1], and despite theoretical benefits there is no convincing clinical evidence that bisoprolol has an advantage [2].
ORGANS AND SYSTEMS Metabolism Bisoprolol can increase serum triglycerides and reduce HDL cholesterol [3].
Urinary tract The lower urinary tract symptoms of benign prostatic hyperplasia in a 60-year-old man worsened antihypertensive treatmentwithbisoprolol[4].Withdrawalresultedinrelief,whereas rechallengecausedrepeateddeterioration.
ã 2016 Elsevier B.V. All rights reserved.
DRUG-DRUG INTERACTIONS See Rifamycins
REFERENCES [1] Neutel JM, Smith DH, Ram CV, Kaplan NM, Papademetriou V, Fagan TC, Lefkowitz MP, Kazempour MK, Weber MA. Application of ambulatory blood pressure monitoring in differentiating between antihypertensive agents. Am J Med 1993; 94(2): 181–7. [2] Wheeldon NM, MacDonald TM, Prasad N, Maclean D, Peebles L, McDevitt DG. A double-blind comparison of bisoprolol and atenolol in patients with essential hypertension. Q J Med 1995; 88(8): 565–70. [3] Lancaster SG, Sorkin EM. Bisoprolol. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in hypertension and angina pectoris. Drugs 1988; 36(3): 256–85. [4] Sein Anand J, Chodorowski Z, Hajduk A. Repeated intensification of lower urinary tract symptoms in the patient with benign prostatic hyperplasia during bisoprolol treatment. Przegl Lek 2005; 62(6): 522–3.